CurifyLabs has announced the closing of a $14 million Series A funding round to support the expansion of its U.S. operations and strengthen supply chain for its 3D printing-enabled, personalised medicine compounding technology.
The Finnish health technology company has developed a Compounding System Solution (CSS) which combines proprietary software, GMP-manufactured excipient bases and 3D printing to automate the preparation of personalised medications. CurifyLabs says its technology is currently used by pharmacies in the U.S. and Europe technology to compound and dispense 'thousands of doses' daily.
The funding round was co-led by Sandwater and HealthCap, with participation from Tesi (Finnish Industry Investment Ltd.) and existing investors, including Lifeline Ventures. U.S. customers and employees also participated in the round. It will be used towards ongoing development of the CurifyLabs platform, including its most recent product, the PharmaPrinter Aurum, which is said to compound up to nine times faster than manual processes.
"This investment reflects the conviction our partners have in what we're building," said Charlotta Topelius, CEO and Founder, CurifyLabs. "We have set a high bar for clinical rigour, product quality, and customer support, and this funding gives us the resources to raise that bar further."
